Kentaro Asanuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kentaro Asanuma has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Takehisa Kitazawa
Chugai Pharmaceutical Co., Ltd. 2 Research Division Yokohama, Japan
35 shared publications - Akihisa Sakamoto
Research Division, Chugai Pharmaceutical, Yokohama, Kanagawa, Japan
34 shared publications - Chai Ling Pang
Research Division, Chugai Pharmabody Research, Singapore, Singapore
34 shared publications - Chiew Ying Yeo
Research Division, Chugai Pharmabody Research, Singapore, Singapore
34 shared publications - Futa Mimoto
Research Division, Chugai Pharmabody Research, Singapore, Singapore
34 shared publications - Haruka Kuroi
Discovery Biologics Department, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan
34 shared publications
Latest Publications
- 25 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF17
Antitumor Activity of Orally Available Cyclic Peptide LUNA18 through Direct Pan-RAS Inhibition across Diverse RAS Genetic Alterations
Although recent extensive efforts led to the landmark discovery of clinically effective KRASG12C inhibitors (KRASG12C-i), targeting RAS genetic alterations beyond the G12C mutant remains challenging. In this study, we report on LUNA18 (paluratide), an orally available cyclic peptide that acts as a first-in-class pan–RAS-GDP inhibitor, exhibiting potent inhibitory activity against a wide variety of RAS mutations. LUNA18 demonstrated antitumor effects against cancer cells with various RAS alterations, including G12 and G13 mutations as well as KRAS amplification. Moreover, LUNA18 showed synergistic antitumor effects when combined with agents targeting receptor tyrosine kinase and the mitogen-activated protein kinase (MAPK) pathway. Notably, under long-term treatment and growth factor stimulation, LUNA18 induced more potent and sustained signal inhibition than KRASG12C-i. LUNA18 can sustain MAPK pathway suppression via RAS wild-type (RAS WT) inactivation, which produces this enhanced inhibitory effect in KRAS-mutant cancers in which RAS WT acts as a critical regulator of MAPK signaling. In xenograft models in which the efficacy of KRASG12C-i was limited, combination with LUNA18 achieved more durable antitumor effects compared with the monotherapies. These findings suggest that LUNA18 could be a promising new therapeutic option for RAS-driven cancers.
- 25 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF17
Antitumor Activity of Orally Available Cyclic Peptide LUNA18 through Direct Pan-RAS Inhibition across Diverse RAS Genetic Alterations
Although recent extensive efforts led to the landmark discovery of clinically effective KRASG12C inhibitors (KRASG12C-i), targeting RAS genetic alterations beyond the G12C mutant remains challenging. In this study, we report on LUNA18 (paluratide), an orally available cyclic peptide that acts as a first-in-class pan–RAS-GDP inhibitor, exhibiting potent inhibitory activity against a wide variety of RAS mutations. LUNA18 demonstrated antitumor effects against cancer cells with various RAS alterations, including G12 and G13 mutations as well as KRAS amplification. Moreover, LUNA18 showed synergistic antitumor effects when combined with agents targeting receptor tyrosine kinase and the mitogen-activated protein kinase (MAPK) pathway. Notably, under long-term treatment and growth factor stimulation, LUNA18 induced more potent and sustained signal inhibition than KRASG12C-i. LUNA18 can sustain MAPK pathway suppression via RAS wild-type (RAS WT) inactivation, which produces this enhanced inhibitory effect in KRAS-mutant cancers in which RAS WT acts as a critical regulator of MAPK signaling. In xenograft models in which the efficacy of KRASG12C-i was limited, combination with LUNA18 achieved more durable antitumor effects compared with the monotherapies. These findings suggest that LUNA18 could be a promising new therapeutic option for RAS-driven cancers.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S6. Cross-reactivity of DLL3 trispecific.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S6. Cross-reactivity of DLL3 trispecific.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S2. Overview of the generation of the CD3/CD137 dual-specific Fab
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S2. Overview of the generation of the CD3/CD137 dual-specific Fab
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S7. DLL3 expression of SCLC xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S7. DLL3 expression of SCLC xenograft models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S4. DLL3 trispecific induces multiple cytokine production and DLL3- dependent cytotoxicity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S4. DLL3 trispecific induces multiple cytokine production and DLL3- dependent cytotoxicity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S8. DLL3 trispecific induced activation of tumor-infiltrating T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S8. DLL3 trispecific induced activation of tumor-infiltrating T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S5. DLL3 trispecific induces cytotoxicity against non-SCLC tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S5. DLL3 trispecific induces cytotoxicity against non-SCLC tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Pharmacokinetic parameters of DLL3 trispecific in cynomolgus monkeys
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S9. The use of dexamethasone and tocilizumab does not limit the antitumor efficacy of DLL3 trispecific.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Supplementary Figure S9. The use of dexamethasone and tocilizumab does not limit the antitumor efficacy of DLL3 trispecific.